Table 1

Demographics and treatment and outcomes of the SF-36 cohort

N (%)
(n=169)
Age (years):
<4924 (14)
49–6980 (47)
>6965 (38)
Gender:
Male106 (63)
Female63 (37)
Symptom onset to hospitalisationMedian (IQR): 8 (4–14) days
Smoking status:
Current8 (6)
Former33 (23)
Never50 (35)
Missing78 (46)
Number of days in the hospitalMedian (IQR): 7 (3–16) days
Chest XR and/or CT consistent with COVID (specific findings):
Pulmonary infiltrates59 (35)
Bilateral and peripheral changes58 (34)
Consolidative pulmonary opacities66 (39)
Small effusion8 (5)
Linear opacities12 (7)
Progressively more bilateral with time/disease severity21 (12)
Age groups (years)
<4949–69>69
(n=24)(n=80)(n=65)
Oxygen therapy:
Oxygen therapy01922
High-flow nasal cannula oxygen therapy114036
Required ICU:
Invasive ventilation6111
ICU/HDU admission7206
Readmission41410
Domiciliary placement:
Transfer to other facility046
Palliative discharge002
Return to care home066
Home with increased care package036
Home with oxygen therapy012
Community bed temporary2514
Same as before226131
  • In the over 69-year-olds, the majority had significant COVID-related SARI to require high-flow oxygen, but only one received critical care support, compared with almost all 49–69-year-olds necessitating high-flow oxygen and critical care support with invasive ventilation.

  • ICU, intensive care unit; SARI, severe acute respiratory infection; SF-36, 36-item short form; XR, X-ray.